BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan, Noam Barda, Eldad Kepten, +7

New England Journal of Medicine

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

Noam Barda, Noa Dagan, Yatir Ben‐Shlomo, +9

New England Journal of Medicine

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

Noam Barda, Noa Dagan, Cyrille J. Cohen, +5

The Lancet

Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge

Ronen Arbel, Yael Wolff Sagy, Moshe Hoshen, +13

New England Journal of Medicine

Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy

Noa Dagan, Noam Barda, Tal Biron‐Shental, +8

Nature Medicine

VaccinologyVaccine SafetyVaccinationMaternal ImmunizationVaccine Development +4

Developing a COVID-19 mortality risk prediction model when individual-level data are not available

Noam Barda, Dan Riesel, Amichay Akriv, +12

Nature Communications

External validation and comparison of three prediction tools for risk of osteoporotic fractures using data from population based electronic health records: retrospective cohort study

Noa Dagan, Chandra J. Cohen-Stavi, Maya Leventer‐Roberts, +1

BMJ

Automated opportunistic osteoporotic fracture risk assessment using computed tomography scans to aid in FRAX underutilization

Noa Dagan, Eldad Elnekave, Noam Barda, +5

Nature Medicine

Bone DiseaseSpinal FractureSkeletal TraumaBone ImagingBone Health +10

BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age

Chandra J. Cohen-Stavi, Ori Magen, Noam Barda, +11

New England Journal of Medicine

Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting

Moshe Mittelman, Ori Magen, Noam Barda, +4

Blood